Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Immunology

• Publication date

  2008-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molimm.2008.06.027PMID 18691763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.

  2008cited by this paper
• A mouse Fcγ-Fcε protein that inhibits mast cells through activation of FcγRIIB, SH2 domain–containing inositol phosphatase 1, and SH2 domain–containing protein tyrosine phosphatases

  2008cited by this paper
• Distinct cell-specific control of autoimmunity and infection by FcγRIIb

  2008cited by this paper
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions.

  2007cited by this paper
• Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus.

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.

  2007cited by this paper
• The Role of Activating Protein 1 in the Transcriptional Regulation of the Human FCGR2B Promoter Mediated by the -343 G → C Polymorphism Associated with Systemic Lupus Erythematosus*

  2007cited by this paper
• FcgammaRIIB as a modulator of autoimmune disease susceptibility.

  2007cited by this paper
• Expression Profile of FcγRIIb on Leukocytes and Its Dysregulation in Systemic Lupus Erythematosus1

  2007cited by this paper
• FcγRIIB as a modulator of autoimmune disease susceptibility

  2007cited by this paper
• Modifications to an Fcγ-Fcɛ fusion protein alter its effectiveness in the inhibition of FcɛRI-mediated functions

  2007cited by this paper
• The antiinflammatory activity of IgG: the intravenous IgG paradox

  2007cited by this paper
• A molecular immunology approach to antibody humanization and functional optimization.

  2007cited by this paper
• Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice

  2007cited by this paper
• Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.

  2007cited by this paper
• Selective dysregulation of the FcγIIB receptor on memory B cells in SLE

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Fcgamma receptors: old friends and new family members.

  2006cited by this paper
• CD 72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes 1

  2006cited by this paper
• The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.

  2006cited by this paper
• CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes1

  2006cited by this paper
• Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients.

  2006cited by this paper
• Engineered antibody Fc variants with enhanced effector function.

  2006cited by this paper
• Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus

  2005cited by this paper
• Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts

  2005cited by this paper
• Restoration of Tolerance in Lupus by Targeted Inhibitory Receptor Expression

  2005cited by this paper
• The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells

  2005cited by this paper
• Antibody engineering for the development of therapeutic antibodies.

  2005cited by this paper
• Dissection of the signalling mechanisms underlying FcgammaRIIB-mediated apoptosis of mature B-cells.

  2004cited by this paper
• Dissection of the signalling mechanisms underlying FcγRIIB-mediated apoptosis of mature B-cells

  2004cited by this paper
• Two Distinct Waves of Membrane-Proximal B Cell Antigen Receptor Signaling Differentially Regulated by Src Homology 2-Containing Inositol Polyphosphate 5-Phosphatase 1

  2004cited by this paper
• Inhibitory Fc Gamma Receptors: From Gene to Disease

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling.

  2003cited by this paper
• Feedback regulation by IgG antibodies.

  2003cited by this paper
• B cell inhibitory receptors and autoimmunity

  2003cited by this paper
• Lipid rafts and B-cell activation

  2002cited by this paper
• Partially Distinct Molecular Mechanisms Mediate Inhibitory FcγRIIB Signaling in Resting and Activated B Cells1

  2001cited by this paper
• Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

  2001cited by this paper
• CD19 Amplification of B Lymphocyte Ca2+ Responses

  2001cited by this paper
• Effects of Src Homology Domain 2 (SH2)-Containing Inositol Phosphatase (SHIP), SH2-Containing Phosphotyrosine Phosphatase (SHP)-1, and SHP-2 SH2 Decoy Proteins on FcγRIIB1-Effector Interactions and Inhibitory Functions1

  2000cited by this paper
• Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease.

  2000cited by this paper
• Immune inhibitory receptors.

  2000cited by this paper
• Fcγ Receptor Iib–Deficient Mice Develop Goodpasture's Syndrome upon Immunization with Type IV Collagen

  2000cited by this paper
• Regulation of B cell receptor-mediated MHC class II antigen processing by FcgammaRIIB1.

  1999cited by this paper
• IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice.

  1999cited by this paper
• Inhibitory Modulation of B Cell Receptor-mediated Ca2+ Mobilization by Src Homology 2 Domain-containing Inositol 5′-Phosphatase (SHIP)*

  1999cited by this paper
• Deletion of Fcγ Receptor IIB Renders H-2b Mice Susceptible to Collagen-induced Arthritis

  1999cited by this paper
• IgG-Mediated Enhancement of Antibody Responses Is Low in Fc Receptor γ Chain-Deficient Mice and Increased in FcγRII-Deficient Mice

  1999cited by this paper
• Role of SHIP in FcgammaRIIb-mediated inhibition of Ras activation in B cells.

  1998cited by this paper
• Cutting Edge: FcγRII-B1 Regulates the Presentation of B Cell Receptor-Bound Antigens

  1998cited by this paper
• Fc gamma RII-B1 regulates the presentation of B cell receptor-bound antigens.

  1998cited by this paper
• Role of SHIP in FcgammaRIIb-mediated inhibition of Ras activation in B cells.

  1998influential reference
• Capture and processing of exogenous antigens for presentation on MHC molecules.

  1997cited by this paper
• Co-ligation of the Antigen and Fc Receptors Gives Rise to the Selective Modulation of Intracellular Signaling in B Cells

  1997cited by this paper
• The complexity of signaling pathways activated by the BCR.

  1997cited by this paper
• Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB.

  1996cited by this paper
• Mechanisms of antigen uptake for presentation.

  1996cited by this paper
• Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FeγRIIB

  1996cited by this paper
• Activation of B lymphocytes: integrating signals from CD19, CD22 and FcγRIIb1

  1996cited by this paper
• Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1.

  1996cited by this paper
• Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes.

  1994cited by this paper
• Reduced life span of anergic self-reactive B cells in a double- transgenic model

  1994cited by this paper
• A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling

  1994cited by this paper
• A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling

  1994cited by this paper
• Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes.

  1992cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Comparison of variable region primary structures within an anti-fluorescein idiotype family.

  1989cited by this paper
• A Unique Human B Lymphocyte Antigen Defined by a Monoclonal Antibody

  1984cited by this paper
• Regulation of the immune response. VI. Inability of F(ab') 2 antibody to terminate established immune responses and its ability to interfere with IgG antibody-mediated immunosuppression.

  1973cited by this paper
• References and Notes Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Sequence-directed Dna Translocation by Purified Ftsk

  year unknowncited by this paper

• New biological agents in systemic lupus erythematosus.

  2026cites this paper
• High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo.

  2025cites this paper
• Combinatorial Fc modifications for complementary antibody functionality

  2025cites this paper
• Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.

  2025cites this paper
• Mapping affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactions

  2025cites this paper
• Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis

  2025cites this paper
• Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies

  2025cites this paper
• FcγRI is the key determinant of antibody-mediated Zika virus infection of human placental macrophages

  2025influential citation
• Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

  2025cites this paper
• SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.

  2025cites this paper
• New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach

  2025cites this paper
• CD19 and FcγRIIb co-engagement inhibits processes essential to T cell-dependent B-cell responses.

  2025cites this paper
• Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy

  2024cites this paper
• Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches.

  2024cites this paper
• Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective

  2024cites this paper
• The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds

  2024cites this paper
• PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation - therapeutic implications for autoimmunity.

  2024cites this paper
• Monoclonal antibodies: From magic bullet to precision weapon

  2024cites this paper
• Using IMGT unique numbering for IG allotypes and Fc‐engineered variants of effector properties and half‐life of therapeutic antibodies

  2024cites this paper
• Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors

  2024cites this paper
• Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcγRIIb binding

  2024cites this paper
• Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis

  2024cites this paper
• Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

  2024cites this paper
• Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations

  2024cites this paper
• Impact of structural modifications of IgG antibodies on effector functions

  2024cites this paper
• New Technologies in Therapeutic Antibody Development: The Next Frontier for Treating Infectious Diseases.

  2024cites this paper
• Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP

  2024cites this paper
• Engineering Therapeutic Monoclonal Antibodies.

  2023cites this paper
• High-fidelity large-diversity monoclonal mammalian cell libraries by cell cycle arrested recombinase-mediated cassette exchange

  2023cites this paper
• Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

  2023cites this paper
• Inhibitory Fc-Gamma IIb Receptor Signaling Induced by Multivalent IgG-Fc Is Dependent on Sialylation

  2023cites this paper
• Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.

  2023cites this paper
• A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns.

  2023cites this paper
• A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases

  2023cites this paper
• Multivalent Scaffolds to Promote B cell Tolerance.

  2023cites this paper
• Preclinical in vitro evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody.

  2023cites this paper
• Age-related changes of the human splenic marginal zone B cell compartment.

  2023cites this paper
• Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination

  2023cites this paper
• Fcγ-receptor-independent controlled activation of CD40 canonical signaling by novel therapeutic antibodies for cancer therapy

  2023cites this paper
• Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies

  2023cites this paper
• Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial

  2023cites this paper
• Antibody interfaces revealed through structural mining

  2022cites this paper
• IMGT® Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats

  2022cites this paper
• Avidity in antibody effector functions and biotherapeutic drug design

  2022cites this paper
• Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking

  2022influential citation
• Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy.

  2022cites this paper
• Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering

  2022cites this paper
• Novel Antibody Interfaces Revealed Through Structural Mining

  2022cites this paper
• Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations.

  2022cites this paper
• Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

  2022cites this paper
• Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges

  2022cites this paper
• APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

  2021cites this paper
• The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases

  2021cites this paper
• FcγRIIB is a T cell checkpoint in antitumor immunity

  2021cites this paper
• Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus.

  2021cites this paper
• Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis

  2021cites this paper
• Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseafses.

  2021cites this paper
• A general Fc engineering platform for the next generation of antibody therapeutics

  2021cites this paper
• Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2

  2021influential citation
• High affinity human Fc specific monoclonal antibodies for capture kinetic analyses of antibody-antigen interactions.

  2021cites this paper
• A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.

  2021cites this paper
• Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection

  2021cites this paper
• On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions

  2021cites this paper
• Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

  2020cites this paper
• Past, present, and future of anti‐IgE biologics

  2020cites this paper
• Domain binding and isotype dictate the activity of anti-human OX40 antibodies

  2020cites this paper
• Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fcγ receptors.

  2020cites this paper
• Nanotechnology-based antiviral therapeutics

  2020cites this paper
• Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

  2020influential citation
• A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus

  2020cites this paper
• Systemic lupus erythematosus (SLE): emerging therapeutic targets

  2020cites this paper
• B cells targeting therapy in the management of systemic lupus erythematosus

  2020cites this paper
• Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs

  2020cites this paper
• Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease

  2019cites this paper
• A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.

  2019cites this paper
• Anti-inflammatory Activity of IgG-Fc.

  2019cites this paper
• Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4Rα therapeutic antibody

  2019cites this paper
• B cell checkpoints in autoimmune rheumatic diseases

  2019cites this paper
• Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.

  2019cites this paper
• Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

  2019cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB

  2018cites this paper
• Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.

  2018cites this paper
• Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.

  2018cites this paper
• FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody

  2018cites this paper
• Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing

  2018cites this paper
• Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies

  2018cites this paper
• Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

  2017cites this paper
• IgG Fc engineering to modulate antibody effector functions

  2017influential citation
• Role of Fc–FcγR interactions in the antitumor activity of therapeutic antibodies

  2017cites this paper
• IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs

  2017cites this paper
• OX40: Structure and function - What questions remain?

  2017cites this paper
• Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities

  2017cites this paper
• Sequence of antibody heavy chain constant region for enhancing agonist antibody activity

  2017cites this paper
• Characterization of Fc gamma receptor IIb expression within abdominal aortic aneurysm.

  2017cites this paper
• Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

  2016cites this paper
• Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life

  2016cites this paper
• Harnessing Fc receptor biology in the design of therapeutic antibodies.

  2016cites this paper
• The Highly Evolvable Antibody Fc Domain.

  2016cites this paper
• Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB

  2016cites this paper